{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:01:54Z","timestamp":1761919314232},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background\/Aims.<\/jats:title>\n                  <jats:p>HIV and hepatitis C virus (HCV) share common modes of transmission, resulting in about 33% incidence of coinfection among people infected with HIV. The survival benefit from highly effective antiretroviral therapy (HAART) for HIV infection is resulting in an increased incidence of hepatocellular carcinoma (HCC) in this population. There are no reports to date regarding the coadministration of HAART and sorafenib for hepatocellular carcinoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>We report the case of a 42-year-old male patient coinfected with HIV and HCV who developed advanced HCC not amenable to curative therapy. The patient was treated with sorafenib, an oral multikinase inhibitor shown to lead to a longer median survival time and time to progression in patients with advanced HCC. Antiretroviral therapy was continued during sorafenib therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The patient achieved a partial tumor response after 3 months and continued to respond at subsequent assessments. His serum \u03b1-fetoprotein normalized from 2,172 IU\/ml to 2 IU\/ml. He had durable stable disease after 23 months of therapy. Antiretroviral therapy was efficacious (CD4+ lymphocyte count, 377\/\u03bcl; HIV viremia, &amp;lt;50 copies\/ml). The simultaneous administration of these therapies was well tolerated. No grade 3 or 4 toxicities were observed. Exacerbation of pre-existing hypertension, grade 2 diarrhea, and grade 1 skin reaction were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>This is the first report in which sorafenib has been successfully used to treat HCC in a patient with HIV\u2013HCV coinfection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2010-0010","type":"journal-article","created":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T01:44:06Z","timestamp":1265679846000},"page":"142-145","source":"Crossref","is-referenced-by-count":14,"title":["Sorafenib Therapy for Hepatocellular Carcinoma in an HIV\u2013HCV Coinfected Patient: A Case Report"],"prefix":"10.1093","volume":"15","author":[{"given":"Giorgio","family":"Perboni","sequence":"first","affiliation":[{"name":"a Infectious Disease Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Costa","sequence":"additional","affiliation":[{"name":"a Infectious Disease Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Carlo","family":"Fibbia","sequence":"additional","affiliation":[{"name":"a Infectious Disease Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Morandini","sequence":"additional","affiliation":[{"name":"a Infectious Disease Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Scalzini","sequence":"additional","affiliation":[{"name":"a Infectious Disease Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Tagliani","sequence":"additional","affiliation":[{"name":"b Radiology Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Cengarle","sequence":"additional","affiliation":[{"name":"c Medical Oncology Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Aitini","sequence":"additional","affiliation":[{"name":"c Medical Oncology Unit, \u201cC. Poma Hospital,\u201d Mantova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,2,8]]},"reference":[{"key":"2021122207232985700_R1","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","article-title":"Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis","volume":"132","author":"El-Serag","year":"2007","journal-title":"Gastroenterology"},{"key":"2021122207232985700_R2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2893.1999.00153.x","article-title":"Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA","volume":"6","author":"Bonacini","year":"1999","journal-title":"J Viral Hepat"},{"key":"2021122207232985700_R3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"2021122207232985700_R4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/319273","article-title":"Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection","volume":"183","author":"Ragni","year":"2001","journal-title":"J Infect Dis"},{"key":"2021122207232985700_R5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.300.1.51","article-title":"Changes in the risk of death after HIV seroconversion compared with mortality in the general population","volume":"300","author":"Bhaskaran","year":"2008","journal-title":"JAMA"},{"key":"2021122207232985700_R6","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2003.01.096","article-title":"Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients","volume":"21","author":"Herida","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122207232985700_R7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.01.009","article-title":"Hepatocellular carcinoma in HIV-infected patients comes of age: The convergence of epidemiology and treatment effectiveness","volume":"50","author":"Sulkowski","year":"2009","journal-title":"J Hepatol"},{"key":"2021122207232985700_R8","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e32831103ad","article-title":"Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma","volume":"22","author":"Clifford","year":"2008","journal-title":"AIDS"},{"key":"2021122207232985700_R9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2007.06.010","article-title":"Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study","volume":"47","author":"Br\u00e4u","year":"2007","journal-title":"J Hepatol"},{"key":"2021122207232985700_R10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejim.2004.09.011","article-title":"Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients","volume":"16","author":"Murillas","year":"2005","journal-title":"Eur J Intern Med"},{"key":"2021122207232985700_R11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1089-3261(02)00074-0","article-title":"Hepatitis C in the HIV-infected patient","volume":"7","author":"Sulkowski","year":"2003","journal-title":"Clin Liver Dis"},{"key":"2021122207232985700_R12","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.164.21.2349","article-title":"Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992\u20132001","volume":"164","author":"Giordano","year":"2004","journal-title":"Arch Intern Med"},{"key":"2021122207232985700_R13","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-148-10-200805200-00005","article-title":"Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992\u20132003","volume":"148","author":"Patel","year":"2008","journal-title":"Ann Intern Med"},{"key":"2021122207232985700_R14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(07)60948-9","article-title":"Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking antiretroviral therapy: An observational cohort study","volume":"370","author":"Mocroft","year":"2007","journal-title":"Lancet"},{"key":"2021122207232985700_R15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"Hepatology"},{"key":"2021122207232985700_R16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-6143.2007.02061.x","article-title":"HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes","volume":"8","author":"Roland","year":"2008","journal-title":"Am J Transplant"},{"key":"2021122207232985700_R17","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1111\/j.1600-6143.2006.01546.x","article-title":"Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C","volume":"6","author":"Vera","year":"2006","journal-title":"Am J Transplant"},{"key":"2021122207232985700_R18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2893.2006.00816.x","article-title":"Therapeutic issues in HIV\/HCV-coinfected patients","volume":"14","author":"Sulkowski","year":"2007","journal-title":"J Viral Hepat"},{"key":"2021122207232985700_R19","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122207232985700_R20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"2021122207232985700_R21","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","article-title":"Molecular targeted therapies in hepatocellular carcinoma","volume":"48","author":"Llovet","year":"2008","journal-title":"Hepatology"},{"key":"2021122207232985700_R22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122207232985700_R23","volume-title":"Bayer HealthCare Pharmaceuticals Inc. Nexavar\u00ae [package insert]"},{"key":"2021122207232985700_R24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/CCO.0b013e32832f3e04","article-title":"Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: Treatment considerations and research outlook","volume":"21","author":"Deeken","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"2021122207232985700_R25","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00280-005-0068-6","article-title":"Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics","volume":"57","author":"Lathia","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122207232985700_R26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.critrevonc.2008.10.013","article-title":"Drug interactions between antineoplastic and antiretroviral therapies: Implications and management for clinical practice","volume":"72","author":"Mounier","year":"2009","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2010-0010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2010-0010","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/2\/142\/41843481\/oncolo_15_2_142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/15\/2\/142\/41843481\/oncolo_15_2_142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T08:28:54Z","timestamp":1640161734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/15\/2\/142\/6399056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2010,2,8]]},"published-print":{"date-parts":[[2010,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2010-0010","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,2,1]]},"published":{"date-parts":[[2010,2,1]]}}}